Charité Ricker

Charité Ricker

Auto-generated profile, based on publicly available information

Charité Ricker

Keck School of Medicine, University of Southern California, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Health Affairs
Verified
Journal Article
Closed access
MRMegan Roberts
Megan Roberts
WDW. David Dotson
W. David Dotson
CDChristopher S. DeVore
Christopher S. DeVore
EBErica M. Bednar
Erica M. Bednar
DBDeborah J. Bowen
Deborah J. Bowen
HHHeather Hampel
Heather Hampel
Cascade screening is the process of contacting relatives of people who have been diagnosed with certain hereditary conditions. Its purpose is to identify, inform, and manage those who are also at risk. We conducted a scoping review to obtain a broad overview of cascade screening interventions, facilitators and barriers to their use, relevant policy considerations, and future research needs. We searched for relevant peer-reviewed literature in the period 1990–2017 and reviewed 122 studies. Finally, we described 45 statutes and regulations related to the use and release of genetic information across the fifty states. We sought standardized best practices for optimizing cascade screening across various geographic and policy contexts, but we found none. Studies in which trained providers contacted relatives directly, rather than through probands (index patients), showed greater cascade screening uptake; however, policies in some states might limit this approach. Major barriers to cascade screening delivery include suboptimal communication between the proband and family and geographic barriers to obtaining genetic services. Few US studies examined interventions for cascade screening or used rigorous study designs such as randomized controlled trials. Moving forward, there remains an urgent need to conduct rigorous intervention studies on cascade screening in diverse US populations, while accounting for state policy considerations.

1 July 2005 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
JWJeffrey N. Weitzel
Jeffrey N. Weitzel
VLVeronica Lagos
Veronica Lagos
KBKathleen R. Blazer
Kathleen R. Blazer
RNRebecca Nelson
Rebecca Nelson
CRCharité Ricker
Charité Ricker
SNSusan Neuhausen
Susan Neuhausen
Approximately 12% of the U.S. population is Hispanic, with the majority residing in urban centers such as Los Angeles. The prevalence of BRCA mutations among high-risk Hispanic families is unknown. Methods: One hundred and ten unrelated probands ofHispanicorigin, with a personal or family history of breast and/orovarian cancer, presented for genetic cancer risk assessment, were enrolled in an Institutional Review Board–approved registry and underwent BRCA testing. Haplotype analyseswere done if BRCA mutations were observed in two or more unrelated probands. Results: Mean age at diagnosis was 37 years (range = 23-59) for the 89 (81%) probands with invasive breast cancer. Overall, 34 (30.9%) had deleterious mutations (25 in BRCA1, 9 in BRCA2), 25 (22.7%) had one or more unclassified variants, and 51 (46.4%) had negative results. The mean pretest mutation probability using the Couch model, Myriad model, and BRCAPro was 19.6% (range = 4-77%). The combined average mutation probability was 32.8% for carriers, 15.5% for noncarriers, and 12.9% for variant carriers (P < 0.0001). The most common deleterious mutation was 185delAG (4 of 34, 11.8%). The Hispanic 185delAG carrier families share the same haplotype from D17s1320 through BRCA1, as do two reference Ashkenazi Jewish families. Haplotype analyses ofadditional recurrent BRCA1 mutations [IVS5+1G>A (n=2),S955X (n = 3), R1443X (n = 3), and 2552delC (n = 2)] also suggest founder effects, with four of six mutations seenalmost exclusively in families with Latin American/Caribbean or Spanish ancestry. Conclusion: This is the largest study to date of high-risk Hispanic families in the United States. Six recurrent mutations accounted for 47% (16 of 34) of the deleterious mutations in this cohort. The BRCA1185delAG mutation wasprevalent (3.6%) in this clinic-based cohort of predominantly Mexican descent, and shared the Ashkenazi Jewishfounder haplotype.

10 January 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JWJeffrey N. Weitzel
Jeffrey N. Weitzel
JCJessica Clague
Jessica Clague
AMArelis Martir-Negron
Arelis Martir-Negron
RORaquel Ogaz
Raquel Ogaz
JHJosef Herzog
Josef Herzog
GLGarrett P. Larson
Garrett P. Larson
Purpose: To determine the prevalence and type of BRCA1 and BRCA2 (BRCA) mutations among Hispanics in the Southwestern United States and their potential impact on genetic cancer risk assessment (GCRA).Patients and Methods: Hispanics (n = 746) with a personal or family history of breast and/or ovarian cancer were enrolled in an institutional review board–approved registry and received GCRA and BRCA testing within a consortium of 14 clinics. Population-based Hispanic breast cancer cases (n = 492) enrolled in the Northern California Breast Cancer Family Registry, negative by sequencing for BRCA mutations, were analyzed for the presence of the BRCA1 ex9-12del large rearrangement.Results: Deleterious BRCA mutations were detected in 189 (25%) of 746 familial clinic patients (124 BRCA1, 65 BRCA2); 21 (11%) of 189 were large rearrangement mutations, of which 62% (13 of 21) were BRCA1 ex9-12del. Nine recurrent mutations accounted for 53% of the total. Among these, BRCA1 ex9-12del seems to be a Mexican founder mutation and represents 10% to 12% of all BRCA1 mutations in clinic- and population-based cohorts in the United States.Conclusion: BRCA mutations were prevalent in the largest study of Hispanic breast and/or ovarian cancer families in the United States to date, and a significant proportion were large rearrangement mutations. The high frequency of large rearrangement mutations warrants screening in every case. We document the first Mexican founder mutation (BRCA1 ex9-12del), which, along with other recurrent mutations, suggests the potential for a cost-effective panel approach to ancestry-informed GCRA.

1 August 2007 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
JWJeffrey N. Weitzel
Jeffrey N. Weitzel
VLVeronica I. Lagos
Veronica I. Lagos
JHJosef S. Herzog
Josef S. Herzog
TJThaddeus Judkins
Thaddeus Judkins
BHBrant Hendrickson
Brant Hendrickson
TSTom Scholl
Tom Scholl
Background: Large rearrangements account for 8% to 15% of deleterious BRCA mutations, although none have been characterized previously in individuals of Mexican ancestry.

1 April 2016 in Cancer Genetics
Verified
Journal Article
Closed access
CRCharité Ricker
Charité Ricker
JCJulie O. Culver
Julie O. Culver
KLKatrina Lowstuter
Katrina Lowstuter
DSDuveen Sturgeon
Duveen Sturgeon
JSJulia D. Sturgeon
Julia D. Sturgeon
SGStephen B. Gruber
Stephen B. Gruber

17 June 2019 in Cancer
Verified
Journal Article
Closed access
PDF file
JWJeffrey N. Weitzel
Jeffrey N. Weitzel
SNSusan L. Neuhausen
Susan L. Neuhausen
AAAaron Adamson
Aaron Adamson
STShu Tao
Shu Tao
CRCharité Ricker
Charité Ricker
EZElad Ziv
Elad Ziv